5/23/2024  9:20:05 PM Chg. -2.27 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
105.10USD -2.11% 36,687
Turnover: 3.89 mill.
-Bid Size: - -Ask Size: - 16.81 bill.USD - -

Business description

Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
 

Management board & Supervisory board

CEO
Charles Dadswell
Management board
Ankur Dhingra, Steve Barnard, Nicole Berry, Aimee Hoyt, Kevin Pegels, Li Qing, Kathryne Reeves, Carissa Rollins, Salli Schwartz, Susan Tousi, Bas Verhoef, Gretchen Weightman
Supervisory board
Stephen P. MacMillan, Frances Arnold, PhD, Caroline Dorsa, Robert S. Epstein, Scott Gottlieb, Gary S. Guthart, Philip Schiller, Sue Siegel, Andrew Teno, Scott B. Ullem, Anna Richo
 

Company data

Name: Illumina Inc.
Address: 5200 Illumina Way,San Diego, California 92122, USA
Phone: +1-858-202-4500
Fax: +1-858-202-4766
E-mail: info@illumina.com
Internet: www.illumina.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 48.29%
IPO date: 7/28/2000

Investor relations

Name: -
IR phone: +1-858-291-6421
IR Fax: -
IR e-mail: ir@illumina.com

Main Shareholders

Others
 
48.29%
Vanguard Group Inc
 
9.87%
Baillie Gifford and Company
 
8.83%
Blackrock Inc.
 
8.51%
Morgan Stanley
 
4.77%
State Street Corporation
 
4.24%
Edgewood Management Llc
 
3.52%
Wellington Management Group, LLP
 
3.33%
Polen Capital Management, LLC
 
3.22%
Others
 
5.42%